Exact Sciences' Cologuard Now Recommended in ACS Guidelines | GenomeWeb

NEW YORK (GenomeWeb) — Exact Sciences today announced that the American Cancer Society's national guidelines on colorectal cancer prevention and early detection have been updated to reflect the commercial availability of the company's Cologuard cancer screening test.

Cologuard detects cancer-associated mutations and blood biomarkers in stool samples and has been shown to identify 92 percent of colorectal cancers in average risk patients with 87 percent specificity using only a single sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.